Polar Asset Management Partners Inc. Has $3.41 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Polar Asset Management Partners Inc. trimmed its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 39.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,547 shares of the company's stock after selling 3,600 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in argenx were worth $3,411,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in shares of argenx by 21.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company's stock worth $21,497,000 after buying an additional 6,161 shares during the last quarter. Park Avenue Securities LLC grew its position in shares of argenx by 40.0% in the fourth quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock valued at $1,042,000 after purchasing an additional 484 shares during the last quarter. Ritholtz Wealth Management increased its stake in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after purchasing an additional 414 shares in the last quarter. Aaron Wealth Advisors LLC grew its holdings in argenx by 10.1% during the 4th quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company's stock valued at $301,000 after buying an additional 45 shares during the last quarter. Finally, Ballentine Partners LLC increased its position in argenx by 21.5% during the fourth quarter. Ballentine Partners LLC now owns 536 shares of the company's stock worth $330,000 after buying an additional 95 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of analyst reports. Wells Fargo & Company raised their target price on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Guggenheim reduced their price target on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Baird R W upgraded argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $698.11.

argenx Stock Performance

Shares of NASDAQ ARGX traded up $12.47 during midday trading on Monday, reaching $578.10. 214,106 shares of the company traded hands, compared to its average volume of 324,887. argenx SE has a 12 month low of $356.38 and a 12 month high of $678.21. The stock's 50-day simple moving average is $591.63 and its 200-day simple moving average is $613.54. The firm has a market cap of $35.30 billion, a PE ratio of -656.93 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. On average, equities research analysts expect that argenx SE will post 3.13 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.